Miejsce diuretyków pętlowych w leczeniu ostrej niewydolności serca by Brycht, Oliwia & Drożdż, Jarosław
104 www.journals.viamedica.pl/folia_cardiologica
Folia Cardiologica 2021 
vol. 16, no. 2, pages 104–111 
DOI: 10.5603/FC.2021.0012 




Address for correspondence: Oliwia Brycht MD, II Klinika Kardiologii, Katedra Kardiologii, Kardiochirurgii i Chorób Naczyń, Uniwersytet Medyczny 
w Łodzi, ul. Pomorska 251, 90–213 Łódź, Poland, e-mail: oliwia.brycht@gmail.com
This article is available in open access under Creative Common Attribution-Non-Commercial-No Derivatives 4.0 International (CC BY-NC-ND 4.0) license, allowing to download 
articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.
Role of loop diuretics in the treatment of acute heart failure
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Abstract
Loop diuretics are used as first-line medications in patients with heart failure as they result in symptomatic improvement 
related to relieving organ congestion. The recommendations regarding the use of loop diuretics are mostly based on 
expert opinion, without preference of specific drugs. Thus, the choice of optimal diuretic treatment strategy in acute 
heart failure requires knowledge about differences in the characteristics of loop diuretics available in Poland, furose-
mide and torasemide. Non-renal pleiotropic effects of torasemide should be also borne in mind. Clinically significant 
differences in the pharmacokinetics and biological effects of furosemide and torasemide have been reflected in multiple 
research studies and meta-analyses published in the recent several years. These studies provided consistent evidence 
for the good safety profile of torasemide, and its superior efficacy in regard to the improvement of exercise tolerance and 
reduced readmissions due to heart failure compared to furosemide. The effect of torasemide on mortality reduction in 
patients with heart failure, seen in some studies, requires further evaluation.
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Heart failure
Heart failure is a clinical syndrome related to impaired 
pump function of the heart, resulting in an inadequate 
blood flow in relation to the tissue demand [1]. In the 
pathomechanism of decompensation in patients with 
heart failure, the major role is played by activation of the 
renin–angiotensin–aldosterone system, which initially 
serves as an adaptive mechanism to preserve adequate 
tissue perfusion and cardiac output. However, increased 
sympathetic activation, vasoconstriction, and excessive 
sodium and water retention ensue rapidly, which quickly 
leads to a significant worsening of heart failure symptoms. 
In the long-term, it leads to myocardial remodelling and 
fibrosis, translating to further disease progression [2]. The 
major factor leading to hospital presentation of patients 
with heart failure is organ congestion, defined as symptoms 
of extracellular fluid accumulation [3].
Role of loop diuretics in the management 
of heart failure
Diuretics are used as first-line medications in patients 
with heart failure as they result in symptomatic impro-
vement related to relieving organ congestion [4]. The 
European guidelines on the management of heart failure 
recommend diuretics to reduce dyspnoea and improve 
exercise tolerance in patients with symptoms of conge-
stion (class of recommendation I, level of evidence B). In 
addition, diuretics should be considered to reduce the 
risk of hospital admission due to heart failure in patients 
with symptoms of congestion (class of recommendation 
IIa, level of evidence B) [1]. Although loop diuretics are 
first-line medications, the recommendations regarding 
their use are mostly based on expert opinion, without 
preference of specific drugs [5]. The choice of optimal 
diuretic treatment strategy in acute heart failure requires 
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administration may be more effective compared to the oral 
dose [4]. Although intestinal mucosal oedema and slow 
blood flow in the duodenum present in heart failure usu-
ally do not affect the bioavailability of orally administered 
drugs, these factors do slow down their absorption, which 
reduces the peak blood level of the drug and may contrib-
ute to resistance to diuretics [15].
In contrast to furosemide, torasemide is characterized 
by higher and more stable bioavailability following oral ad-
ministration (> 90%), which is much dependent on con-
comitant food intake and pH of the gastric contents [16]. 
Torasemide does not show intestinal absorption-limited 
pharmacokinetics, which is associated in higher equiva-
lence of oral and intravenous doses [15]. The drug is me-
tabolized in the liver to inactive metabolites, in contrast 
to furosemide which is mostly excreted by the kidneys [4]. 
Torasemide has a longer half-life (3–4 h) than furosemide 
(1.5–2 h). In heart failure, the half-life increases to 6 h for 
torasemide and 2.7 h for furosemide [13].
Loop diuretics are organic anions circulating in the form 
of complexes with plasma proteins (> 90%) which limits 
their distribution volume [4].
Selected pharmacokinetic properties of furosemide and 
torasemide are shown in Table 1 [16–18].
Comparison of pharmacodynamics  
of torasemide and furosemide
The onset of action of furosemide and torasemide is within 
10 minutes after intravenous administration. The initial 
observed effect is venous vasodilation [9]. Clinically, it 
reduces dyspnoea which is often the major complaint in 
patients with exacerbation of chronic heart failure. Later, 
these drugs induce diuresis secondary to NKCC2 inhibition 
in the nephron as described above [13].
Torasemide and furosemide differ in their potency. 
A double-blind randomized study published in 1986 which 
compared the diuretic effect of these two drugs showed 
a relative increase in urine volume by 68% with torase-
mide compared to furosemide. In addition, a reduction in 
diuresis at 12 hours after furosemide administration was 
observed, while this effect was not seen after administra-
tion of torasemide [17].
In contrast to furosemide, torasemide shows pleiotro-
pic effects in organs other that the kidneys [16]. Initially, is 
was observed that torasemide results in lower urinary po-
tassium excretion, an effect similar to that of mineralocor-
toicoid receptor blockade [19]. Later, animal studies con-
firmed an anti-aldosterone effect of torasemide by block-
ing aldosterone binding to the mineralocortoicoid receptor 
[20], inhibition of aldosterone secretion [21], and changes 
in the expression of genes participating in the pathomech-
anism of myocardial fibrosis [22]. These effects were not 
demonstrated for furosemide. The anti-aldosterone effect 
knowledge about differences in the characteristics of loop 
diuretics available in Poland.
Mechanism of action of loop diuretics
Loop diuretics available in Poland include furosemide and 
torasemide. Other drugs from this class, such as azose-
mide and bumetanide, are not available in Poland. The 
mechanism of action of loop diuretics involves inhibiting 
ATP-dependent sodium-potassium-2 chloride cotransporter 
(NKCC2) located on the luminal surface of the endothe-
lial cells within the thick part of the ascending arm of 
the loop of Henle. Inhibition of this cotransporter blocks 
reabsorption of up to 25% of sodium filtered into the 
primary urine, and this effect is responsible for the most 
of the natriuretic effect of loop diuretics [6]. In addition, 
loop diuretics inhibit the same cotransporter at the apical 
membrane of the macula densa, stimulating renin secretion 
[7] and blocking the tubuloglomerular feedback [8] — these 
effects may contribute to preservation of the glomerular 
filtration rate [4]. Loop diuretics also inhibit the other 
isoform of this transporter, sodium-potassium-1 chloride 
cotransporter (NKCC1), which is expressed in the whole 
body. This effect results in an increased prostaglandin 
synthesis and venous smooth muscle relaxation, leading 
to increased venous pooling [9]. The NKCC1 isoform is 
also expressed in the hearing organ, and this local action 
of diuretics within the ear likely explains their ototoxicity 
[10]. Other adverse effects of diuretics include electrolyte 
disturbances such as hypokalaemia, hypomagnesaemia, 
hypocalcaemia, hyponatraemia, along with hyperuricaemia 
and dysglycaemia [5, 11].
Comparison of pharmacokinetics  
of torasemide and furosemide
Furosemide was introduced to hospital practice in 1966 
and it remains the most commonly used loop diuretic. To-
rasemide was introduced in the United States in 1993 [12].
Following oral administration, furosemide is charac-
terized by limited and variable bioavailability, or the ratio 
of the absorbed drug to the dose administered orally. The 
average bioavailability of furosemide is 50% but it ranges 
from 10% to 100% [13]. Food intake delays furosemide ab-
sorption, reducing its peak blood level [4]. As the drug half- 
-life is shorter than its rate of gastrointestinal absorption, it 
showed an absorption-limited pharmacokinetics [14] which 
means that the actual half-life following oral administration 
is longer than the half-life after intravenous administration. 
In patients with preserved renal function, furosemide ad-
ministered intravenously is roughly twice more potent per 
mg compared to oral administration. However, with severe 
sodium retention in exacerbated chronic heart failure, 
a higher peak drug level may be required and intravenous 
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of torasemide in the comparative study with furosemide 
[23], which may reduce myocardial fibrosis, also trans-
lated to a dose-dependent improvement of clinical heart 
failure markers, such as natriuretic peptide levels and 
echocardiographic parameters of left ventricular function. 
The anti-aldosterone component of the torasemide action 
may be associated with a reduced risk of hypokalaemia 
and hypomagnesaemia during intensive combined diuret-
ic therapy [24]. Another advantage is absence of sympa-
thetic activation during torasemide treatment [25]. In ad-
dition, torasemide may show benefits in regard to the risk 
of acute kidney injury. This property was shown in a meta-
analysis of randomized studies comparing torasemide to 
other loop diuretics [26]. A protective effect on the kidney 
function may be due to an increased secretion of vasodi-
lating prostacyclin, the effect that is more pronounced fol-
lowing torasemide administration compared to furosemide 
[27]. In addition, furosemide, but not torasemide, stimu-
lates release of thromboxane, a physiological prostacyclin 
antagonist, in both patients with congestive heart failure 
and healthy controls [27]. Another possible benefit from 
the use of torasemide may be a lower risk of ototoxicity. 
In studies in cats, the dose resulting in a certain level of 
hearing impairment in 50% of animals was slightly higher 
for torasemide compared to furosemide. Hearing impair-
ment tended to improve following the acute phase. In ad-
dition, the major metabolite of torasemide did not exert an 
ototoxic effect even in large doses [28].
Selected pharmacodynamic properties of furosemide 
and torasemide are shown in Table 2 [16–18].
Renal function and loop diuretics
The common effect of diuretics is a reduction of intravascu-
lar volume. A secondary effect is a return of extravascular 
fluid to restore intravascular volume excreted with urine, 
known as ‘refilling’ [18]. This effect allows gradual reduction 
of organ congestion, or fluid accumulation in the extrava-
scular compartment — interstitial tissue and body cavities. 
Use of high-dose diuretic therapy, resulting in a reduction 
of intravascular volume, is associated with haemoconcen-
tration which has been identified as a factor leading to 
transient renal function worsening [29]. The major cause 
of this problem is likely a disproportion between the diu-
resis rate and the refilling rate [18], resulting in relative 
hypovolemia and secondary neural activation accompanied 
Table 1. Comparison of selected pharmacokinetic properties of furosemide and torasemide (based on [16–18])
Parameter Furosemide Torasemide
Bioavailability following oral administration [%] 10–90 
(interindividual variability)
80–90
Effect of food on complete absorption Yes No
Relative potency 1 × 2 ×
Binding with plasma proteins [%] 95 99
Half-life in healthy individuals [h] 1.5–2 3–4
Half-life in chronic kidney disease [h] 2.8 4–5
Half-life in heart failure [h] 2.7 6
Duration of action after intravenous administration [h] 6–8 6–16
Onset of action after intravenous administration [min] 10 8
Peak level after oral administration [h] 1 1
Intravenous to oral dose equivalence ratio 2:1 1:1
Hepatic metabolism (%) No 80%
Renal excretion 50% conjugates Mainly in the form  
of inactive metabolites
Table 2. Comparison of selected pharmacodynamics properties of furosemide and torasemide (based on [16–18])
Parameter Furosemide Torasemide
Vasodilating effect preceding the diuretic effect Yes Yes
Reduction of kaliuresis No Yes
Activation of the renin–angiotensin–aldosterone system Yes No or minimal
Sympathetic activation Yes No
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by arterial constriction, leading to a risk of peripheral organ 
ischaemia. One marker of relative hypovolemia and severe 
neuroactivation in heart failure is urea retention [30]. To 
counteract these processes, a concept has been advanced 
that the goal of safe therapy of congestion in heart failure 
should be to keep the diuresis rate during diuretic drug 
therapy at the level not exceeding the refilling rate [1, 31]. 
By extrapolating the experience from renal replacement 
therapy to diuretic treatment, it may be supposed that ex-
ceeding the refilling rate is more likely when ultrafiltration 
is too large over a short time, while the effectiveness of 
refilling should improve when ultrafiltration is extended 
over time [32]. Hence, prolonging the duration of a diuretic 
effect by the use of a long-acting diuretic, torasemide, ad-
ministered in dosing intervals consistent with its duration 
of action, should be more effective in this regard [18]. 
Figure 1 shows practical aspects of furosemide and tora-
semide use, including episodic occurrence of the effects 
of profound diuresis following furosemide administration, 
which may contribute to symptomatic hypotension in the 
treated patients, and possible reduction in the urine output 
following cessation of the diuretic action, which may lead 
to clinically observed recurrent symptoms of congestion, 
for example in the pulmonary circulation.
When planning the management in a patient with heart 
failure, due attention should be paid to the phenomenon of 
diuretic resistance, which may occur in as many as 25–30% 
of patients with this clinical syndrome. The occurrence of 
the diuretic resistance phenomenon may be expected in 
patients with hypotension, chronic kidney disease, and 
atherosclerosis. The multiple underlying factors include 
changes in drug pharmacokinetics, hormonal dysregula-
tion, and the cardiorenal syndrome. The management of 
patients with diuretic resistance includes sequential neph-
ron blockade using diuretics from two different classes, 
renal replacement therapy by ultrafiltration or peritoneal 
dialysis, and aspiration of peritoneal fluid in patients with 
increased intraabdominal pressure [33]. However, the 
most commonly used approach is to increase the doses 
of diuretics drugs to promote a negative fluid and sodium 
balance. Torasemide, which is characterized by a nearly 
unchanged half-life in the settings of impaired renal func-
tion [16], provides an effective dose-dependent increase in 
diuresis and natriuresis when used in high doses, even in 
patients with advanced chronic kidney disease. Two multi-
centre clinical trials which compared high furosemide and 
torasemide doses in patients with end-stage renal disease 
undergoing haemodialysis showed a large increase in urine 
output and ion excretion in patients treated with 100 mg 
or 200 mg torasemide once daily orally. The oral daily to-
rasemide dose of 200 mg resulted in a similar natriuretic 
effect compared to the oral furosemide dose of 500 mg, 
with more potent blood pressure-lowering effect of torase-
mide. Both torasemide and furosemide in these doses had 
no negative effect on the neurological status of patients 
treated with haemodialysis [34].
Torasemide 200 mg preparation is available in Poland 
for the treatment of patients with severe chronic kidney 
disease (creatinine clearance < 20 mL/min and/or serum 
creatinine level > 6 mg/dL). The indication for its use is 
the intent to preserve diuresis, and the presence of oede-
ma, transudate, and high blood pressure in patients with 
severe renal failure, including dialyzed patients, if the re-
sidual diuresis exceeds 200 mL/day.
Clinical studies comparing torasemide  
and furosemide
The extremely clinically important differences in the phar-
macokinetic properties and biological effects of furosemide 
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and torasemide have been reflected in many research 
studies published in the last several years that evaluated 
the efficacy and safety of torasemide. The comparator is 
most of these studies was furosemide, a diuretic commonly 
used for many years.
In an open German study [35] in 1650 patients to 
compare the clinical efficacy of torasemide and furosemi-
de, it was shown that torasemide resulted in the greatest 
improvement in exercise tolerance in patients with initial-
ly severe symptoms and/or those diuretic-naïve. Patients 
previously treated with a diuretic benefited from a switch 
to torasemide. No adverse effects on potassium, uric acid, 
and glucose levels were observed in the torasemide group. 
In that study, 95% of physicians and 93% of patients posi-
tively rated their experiences with torasemide treatment. 
In a one-year open randomized study [36] in 234 pa-
tients that compared furosemide and torasemide, patients 
treated with torasemide had a lower rate of readmissions 
due to heart failure (17% vs. 32% in the furosemide group) 
and cardiovascular hospitalizations (44% vs. 59% in the 
furosemide group). In addition, patients treated with tora-
semide spent fewer days in hospital due to heart failure, 
and reported better improvement in terms of dyspnoea and 
fatigue. Reduction in hospitalization due to heart failure 
observed during torasemide therapy translates to a lower 
cost of treating patients with chronic heart failure despite 
a higher cost of drug acquisition [37, 38].
Nine-month open randomized study [39] in 237 pa-
tients with decompensated heart failure evaluated the 
quality of life of patients treated with torasemide or furo-
semide. Compared to furosemide, torasemide resulted in 
a significant symptom improvement [by at least one New 
York Heart Association (NYHA) class] and was associated 
with better treatment tolerance, lower number of micturi-
tions at 3, 6, and 12 hours after dosing, and lower severity 
of urgency. Despite a milder, and thus more comfortable 
diuretic action profile, torasemide resulted in twice higher 
reduction in body weight that served as a surrogate mea-
sure of fluid overload.
The purpose of open, nonrandomized TORIC study 
[40] was to compare 1377 patients with NYHA class II–III 
heart failure who received oral treatment with torasemide 
10 mg/day, furosemide 40 mg/day or other diuretics orally 
for 12 months in addition to standard heart failure therapy. 
Treatment safety and tolerance, mortality, NYHA function-
al class, and blood potassium level were evaluated every 
3 months. Overall mortality was 51.5% lower (p < 0.05), and 
cardiovascular mortality 59.7% lower (p < 0.05) in the to-
rasemide group. In addition, clinical improvement was not-
ed more frequently in the torasemide group (p < 0.00017). 
Treatment with torasemide was associated with less fre-
quent adverse effects — potassium level below 3.5 mmol/L 
was noted in 12.9% of patients treated with torasemide, 
compared to 17.9% of patients treated with furosemide 
(p = 0.013). In addition, potassium supplementation was 
required in only 3% of patients treated with torasemide, 
compared to 30% of patients treated with furosemide.
In a multicentre double-blind randomized study [41], 
6-week therapy with torasemide 10 mg/day, torasemide 
20 mg/day and furosemide 40 mg/day was compared in 
70 patients with chronic heart failure who were previously 
treated with furosemide 40 mg/day for at least 2 weeks. 
A significant reduction in body weight was noted in all three 
groups but this effect was significantly greater in the to-
rasemide 20 mg group at 4 and 6 weeks compared to fu-
rosemide and in the torasemide 10 mg group at 4 weeks 
compared to furosemide. At 6 weeks, the torasemide 20 mg 
group also showed significantly less severe oedema com-
pared to furosemide (p = 0.001).
Initial results of the Polish multicentre randomized 
TORNADO study were also reported [42]. This study was 
conducted in 40 patients with NYHA functional class II–IV 
previously treated with furosemide who were assigned to 
the treatment with equipotent torasemide dose or con-
tinuation of furosemide at the same dose. During the fol-
low-up, 7 patients were hospitalized due to exacerbation 
of heart failure, including 3 patients in the torasemide 
group and 4 patients in the furosemide group. The com-
bined endpoint evaluated at 3 months of treatment was 
defined as improved NYHA class, improvement by at least 
50 m in the 6-minute walking test, and reduction of ob-
jectively evaluated congestion. This endpoint was reached 
by 94% of patients in the torasemide group and 58% of 
patients in the furosemide group (p = 0.03), indicating 
an advantage of torasemide over furosemide in reducing 
congestion and heart failure symptoms as early as after 
3 months of therapy.
The ongoing multicentre randomized TRANSFORM-HF 
study [43] should also be noted. This study will be con-
ducted in the so far largest group of 6,000 patients hospi-
talized due to heart failure who will be randomized to oral 
furosemide or torasemide before the hospital discharge.
Meta-analyses and systematic reviews 
comparing torasemide and furosemide
Meta-analyses of small randomized studies [44, 45] sho-
wed that compared to placebo, loop and thiazide diuretics 
increase exercise tolerance, reduce hospitalizations due to 
exacerbated heart failure, and even reduce the mortality 
risk by more than 70%. Due to a small number of deaths 
in the study groups, however, the results of these meta-
-analyses should be interpreted with caution.
A meta-analysis of randomized studies [46] compar-
ing the efficacy of torasemide and furosemide in 471 pa-
tients with systolic heart failure showed that torasemide 
reduced hospitalizations due to heart failure and cardio-
vascular hospitalizations. In addition, a 14% reduction in 
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the total mortality in the torasemide group was noted but 
this effect was statistically not significant.
In a later meta-analysis of randomized studies [26] 
comparing the efficacy of torasemide with other loop diu-
retics in 2,647 patients, no differences in the overall and 
cardiovascular mortality were noted but fewer hospitaliza-
tions occurred in the torasemide group.
However, a dose-dependent association between loop 
diuretic use and the mortality risk was also noted in pa-
tients with advanced heart failure of ischaemic aetiol-
ogy [47]. In contrast to these results, it was showed that 
a higher loop diuretic dose prescribed at discharge after 
a hospitalization due to exacerbated chronic heart failure 
with reduced ejection fraction reduced the risk of read-
mission within 30 days [48]. It is believed that the need to 
use a higher loop diuretic dose indicates a higher severity 
of heart failure but is not the cause for worse outcomes in 
these patients [49].
In the meta-analysis [50] of 19 studies (9 random-
ized controlled and 10 observational) published in 1996– 
–2019 which included 19,280 patients with heart failure 
treated with torasemide and furosemide, with the mean fol-
low-up of 15 months, a lower risk of hospitalization due to 
heart failure was shown in the torasemide group compared 
to furosemide (10.6% torasemide, 18.4% furosemide; odds 
ratio [OR] 0.72, 95% confidence interval [CI] 0.51–1.03, 
p = 0.07). Torasemide use was associated with a signifi-
cantly higher chance of improvement from NYHA class III–IV 
to class I–II (72.5% torasemide, 58% furosemide; OR 2.32, 
95% CI: 1.32–4.1, p = 0.004) and a lower risk of death due 
to cardiovascular causes (1.5% torasemide, 4.4% furose-
mide; OR 0.37, 95% CI: 0.20–0.66, p < 0.001) compared 
to furosemide. However, no reduction in the total mortality 
or adverse effects was shown.
In another meta-analysis [51] of 54 randomized con-
trolled studies in 10,740 patients with heart failure, vari-
ous diuretic treatment was compared. This study showed 
that compared to furosemide, torasemide treatment over 
1.5–5.6 months of follow-up reduced oedema (relative risk 
1.54, 95% CI: 1.01–2.35) and resulted in a greater reduc-
tion of blood natriuretic peptide levels. This study showed 
no differences between various diuretics in the rates of ad-
verse effects involving various organs, and no differences 
in readmissions and mortality.
Summary
Heart failure is a major challenge for modern cardiology, 
and also an important problem for healthcare management 
systems due to its large economic and social burden [52]. 
The most important limitation for widespread use of tora-
semide remains the lack of evidence from appropriately 
large, prospective, randomized, placebo-controlled studies. 
However, as performing such studies in patients with full-
-blown symptomatic acute exacerbated heart failure may 
not be possible, the optimal drug therapy must be guided by 
the available clinical study results and these suggest that in 
patients with acute exacerbated heart failure, torasemide is 
an appropriate alternative for commonly used furosemide. 
A wider use of torasemide, which is characterized by better 
pharmacological properties, a longer and more potent ef-
fect, and a documented reduction of the readmission rate, 
seems more appropriate from the clinical and economic 
perspective.
Streszczenie
Leki moczopędne podaje się w farmakoterapii pierwszego rzutu u pacjentów z niewydolnością serca, ponieważ powodu-
ją poprawę objawową w zakresie zastoju narządowego. Podstawą zaleceń dotyczących stosowania diuretyków pętlowych 
są głównie opinie ekspertów, bez wskazania konkretnego leku. Wybór optymalnej strategii leczenia moczopędnego 
w ostrej niewydolności serca wymaga zatem od zespołu lekarskiego wiedzy na temat różnic we właściwościach i specy-
fice działania dostępnych na polskim rynku diuretyków pętlowych — furosemidu i torasemidu. Należy również pamiętać 
o plejotropowym działaniu torasemidu wykraczającym poza lokalizację nerkową. Istotne klinicznie różnice pod względem 
właściwości farmakokinetycznych i efektów biologicznych furosemidu i torasemidu znalazły odzwierciedlenie w wielu 
badaniach naukowych oraz metaanalizach opublikowanych w ostatnich kilkunastu latach. W badaniach tych konse-
kwentnie potwierdzano dobry profil bezpieczeństwa torasemidu, jak również wykazano większą skuteczność torasemidu 
w zakresie poprawy wydolności fizycznej u pacjentów oraz zmniejszenie częstości ponownych hospitalizacji z powodu 
niewydolności serca w porównaniu z furosemidem. Tematem dalszych dociekań pozostaje potwierdzony w niektórych 
badaniach wpływ torasemidu na zmniejszenie śmiertelności u pacjentów z niewydolnością serca.
Słowa kluczowe: niewydolność serca, diuretyki pętlowe, torasemid, furosemid, przewlekła choroba nerek
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